Jefferies has begun coverage of Innovex, a US-based contract research and pharmaceutical services firm, with a buy rating and a price target of $34 per share. The initiation of coverage comes as the company continues to expand its clinical development and commercialisation capabilities, which analysts believe will underpin near-term earnings momentum.
The $34 target represents a notable premium to Innovex's current trading levels, suggesting Jefferies sees significant upside potential. The bank's analysts pointed to the firm's strong order book and its ability to secure new contracts in an increasingly competitive outsourcing market as key drivers for the positive outlook.
Innovex operates in the contract development and manufacturing organisation (CDMO) space, a sector that has seen steady demand from pharmaceutical companies seeking to cut costs and accelerate drug development timelines. Jefferies' endorsement may reassure investors who have been cautious amid broader market volatility.
For UK investors, the news offers a glimpse into the health of the global pharmaceutical supply chain, which directly impacts London-listed peers such as Clinigen and Dechra Pharmaceuticals. A rising tide in the CDMO sector could lift sentiment across related stocks on the FTSE 250.
The coverage initiation arrives as the FTSE 250 edged up 0.3% to 20,450 points in midday trading, with healthcare stocks among the gainers. Analysts at Jefferies declined to comment further on the valuation methodology, but the buy rating will likely be watched by institutional funds with exposure to the sector.
Source: Jefferies equity research report